GlobeNewswire·Nov 11, 2026, 7:30 AM ET

BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026

BBIO

BridgeBio Pharma will present 28 abstracts on acoramidis for ATTR-CM at the XX International Symposium on Amyloidosis (ISA) 2026 in Montevideo, Uruguay, scheduled for November 15-18, 2026.
The presentation lineup includes 12 new posters, seven encore poster presentations, and nine encore posters.
BridgeBio's European licensing partner, Bayer, will present five new sessions, including real-world data from Germany comparing acoramidis with tafamidis regarding oral diuretic intensification.
Acoramidis is approved as Attruby® in the U.S. Singapore, as BEYONTTRA® in the EU, Japan, Switzerland, UK, Brazil, Australia, and other regions.
The drug is the only selective, orally administered small molecule TTR stabilizer that achieves near-complete (≥90%) stabilization of transthyretin.
New posters will cover safety, efficacy, cardiorenal function, eGFR dip analysis, treatment patterns, time-to-benefit, indirect comparisons with tafamidis, & cohort studies from the ATTRibute-CM trial.
Encore presentations will focus on mortality reduction, long-term effects on variant ATTR-CM, kidney function protection, prognostic measures, & real-world comparative effectiveness.
Encore posters will address falls, fractures, serum TTR variability, myocardial structure recovery, hospitalization risks, budget impact, & outcomes in female patients.
A specific Bayer-led poster will discuss the mODIficATTR study on oral diuretic intensification in real-world ATTR-CM patients.
Attruby is indicated to reduce cardiovascular death hospitalizations in adults with wild-type or variant ATTR-CM.
Adverse reactions reported for Attruby include diarrhea (11.6%) upper abdominal pain (5.5%), with discontinuation rates similar to placebo (9.3% vs 8.5%).

Company: BridgeBio Pharma, Inc.
Keywords: Nasdaq:BBIO, BridgeBio Pharma, Inc.